Cormedix Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Cormedix Inc. on July 15, 2013, reporting events occurring on July 9, 2013. The filing addresses the company's status regarding continued listing standards on the NYSE MKT.
Key Financial Metrics
The filing does not provide current revenue, profit, cash flow, or debt figures. However, it references the company's Form 10-K for the fiscal year ended December 31, 2012, noting that stockholders' equity was less than $2 million as of that date. The company has sustained substantial losses in two of its three most recent fiscal years.
Material Changes and Listing Status
On July 9, 2013, the NYSE MKT granted Cormedix an extension until October 20, 2013, to regain compliance with two specific listing standards:
- Section 1003(a)(iv): Concerns substantial sustained losses and impaired financial condition raising questions about the ability to continue operations.
- Section 1003(a)(i): Concerns stockholders' equity of less than $2 million and net losses in two of the three most recent fiscal years.
This extension represents the maximum 18-month period allowed from the initial deficiency letters (dated April 2012 and April 2013). No further extensions are permitted beyond October 20, 2013.
Outlook, Risks, and Contingencies
The primary risk identified is the potential delisting of the company's securities. If Cormedix fails to meet the requirements of both Section 1003(a)(i) and Section 1003(a)(iv) by the October 20, 2013 deadline, the NYSE MKT will initiate delisting proceedings. The company has submitted a plan of compliance to address these deficiencies.
Investor Verification Checklist
- Verify the specific details of the compliance plan submitted to the NYSE MKT on May 6, 2013.
- Confirm the company's stockholders' equity and net loss figures as of the most recent reporting period to assess progress toward the $2 million equity threshold.
- Monitor for any subsequent filings indicating failure to meet the October 20, 2013 deadline.
- Review the attached press release (Exhibit 99.1) for additional management commentary on the path to compliance.